Publisher Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.

Autor: Li R; Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. Roger.Li@moffitt.org.; Department of Immunology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. Roger.Li@moffitt.org., Shah PH; Department of Urology, Mayo Clinic, Rochester, MN, USA., Stewart TF; Department of Medicine, UC San Diego, La Jolla, CA, USA., Nam JK; Pusan National University, Yangsan Hospital, Yangsan, South Korea., Bivalacqua TJ; Department of Urology, University of Pennsylvania, Philadelphia, PA, USA., Lamm DL; BCG Oncology, Phoenix, AZ, USA., Uchio EM; Department of Urology, UC Irvine, Irvine, CA, USA., Geynisman DM; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA., Jacob JM; Department of Urology, SUNY Medical Center, Upstate, Syracuse, NY, USA., Meeks JJ; Department of Urology, Northwestern University Medical Center, Chicago, IL, USA., Dickstein R; Chesapeake Urology, Hanover, MD, USA., Pearce SM; Spokane Urology, Spokane, WA, USA., Kang SH; Korea University, Anam Hospital, Seoul, South Korea., Jung SI; Chonnam National University, Hwasun Hospital, Bundang, South Korea., Kamat AM; Department of Urology, UT MD Anderson Cancer Center, Houston, TX, USA., Burke JM; Billings Clinic, Billings, MT, USA., Keegan KA; CG Oncology, Irvine, CA, USA.; Department of Urology, Vanderbilt University, Nashville, TN, USA., Steinberg GD; Department of Urology, Rush University Medical Center, Chicago, IL, USA.

Publikováno v: Nature medicine [Nat Med] 2024 Aug; Vol. 30 (8), pp. 2377.

The Safety, Tolerability, and Preliminary Efficacy of a Gemcitabine-releasing Intravesical System (TAR-200) in American Urological Association-defined Intermediate-risk Non-muscle-invasive Bladder Cancer Patients: A Phase 1b Study.

Autor: P van Valenberg FJ; Department of Urology, Radboudumc, Nijmegen, The Netherlands.; Department of Urology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands., van der Heijden AG; Department of Urology, Radboudumc, Nijmegen, The Netherlands., Cutie CJ; Janssen Research & Development, Lexington, MA, USA., Bhanvadia S; Janssen Research & Development, Lexington, MA, USA., Keegan KA; Janssen Research & Development, Lexington, MA, USA.; Department of Urology, Vanderbilt University, Nashville, TN, USA., Hampras S; Janssen Research & Development, Raritan, NJ, USA., Sweiti H; Janssen Research & Development, Spring House, PA, USA., Maffeo JC; Janssen Research & Development, Lexington, MA, USA., Jin S; Janssen Research & Development, Lexington, MA, USA., Chau A; Datacision Limited, London, UK., Reynolds DL; Janssen Research & Development, Lexington, MA, USA., Iarossi C; Janssen Research & Development, Lexington, MA, USA., Kelley A; Janssen Research & Development, Lexington, MA, USA., Li X; Janssen Research & Development, Raritan, NJ, USA., Stromberg KA; Janssen Research & Development, Raritan, NJ, USA., Michiel Sedelaar JP; Department of Urology, Radboudumc, Nijmegen, The Netherlands., Steenbruggen JJO; Department of Urology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands., Somford DM; Department of Urology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands., Alfred Witjes J; Department of Urology, Radboudumc, Nijmegen, The Netherlands.

Publikováno v: European urology open science [Eur Urol Open Sci] 2024 Feb 16; Vol. 62, pp. 8-15. Date of Electronic Publication: 2024 Feb 16 (Print Publication: 2024).

Reply by Authors.

Autor: Tyson MD; Mayo Clinic Arizona, Phoenix, Arizona., Morris D; Urology Associates, Nashville, Tennessee., Palou J; Fundació Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain., Rodriguez O; Fundació Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain., Mir MC; Fundacion Instituto Valenciano de Oncologia, Valencia, Spain., Dickstein RJ; Chesapeake Urology, Baltimore, Maryland., Guerrero-Ramos F; University Hospital 12 de Octubre, Madrid, Spain., Scarpato KR; Vanderbilt University Medical Center, Nashville, Tennessee., Hafron JM; Michigan Institute of Urology, Troy, Michigan., Messing EM; University of Rochester, Rochester, New York., Cutie CJ; Janssen Research & Development, Lexington, Massachusetts., Maffeo JC; Janssen Research & Development, Lexington, Massachusetts., Raybold B; Janssen Research & Development, Spring House, Pennsylvania., Chau A; Datacision Limited, London, United Kingdom., Stromberg KA; Janssen Research & Development, Raritan, New Jersey., Keegan KA; Vanderbilt University Medical Center, Nashville, Tennessee.; Janssen Research & Development, Lexington, Massachusetts.

Publikováno v: The Journal of urology [J Urol] 2023 May; Vol. 209 (5), pp. 900. Date of Electronic Publication: 2023 Apr 07.

The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trial.

Autor: Daneshmand S; Department of Urology, University of Southern California Keck School of Medicine, Norris Comprehensive Cancer Center, Los Angeles, CA. Electronic address: daneshma@med.usc.edu., Brummelhuis ISG; Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands., Pohar KS; Department of Urology, College of Medicine, The Ohio State University, Columbus, OH., Steinberg GD; Department of Urology, NYU Langone Health, New York, NY., Aron M; Department of Pathology, University of Southern California Keck School of Medicine, Los Angeles, CA., Cutie CJ; Janssen Research & Development, Lexington, MA., Keegan KA; Janssen Research & Development, Lexington, MA., Maffeo JC; Janssen Research & Development, Lexington, MA., Reynolds DL; Janssen Research & Development, Lexington, MA., Raybold B; Janssen Research & Development, Spring House, PA., Chau A; Datacision Limited, London, UK., Witjes JA; Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.

Publikováno v: Urologic oncology [Urol Oncol] 2022 Jul; Vol. 40 (7), pp. 344.e1-344.e9. Date of Electronic Publication: 2022 Apr 14.

Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial.

Autor: Mitra AP; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Narayan VM; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Mokkapati S; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Miest T; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Boorjian SA; Department of Urology, Mayo Clinic, Rochester, MN, USA., Alemozaffar M; Department of Urology, Kaiser Permanente Los Angeles, Los Angeles, CA, USA., Konety BR; Department of Urology, Rush Medical College, Chicago, IL, USA., Shore ND; Carolina Urologic Research Center, Myrtle Beach, SC, USA., Gomella LG; Department of Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA., Kamat AM; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bivalacqua TJ; Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University, Baltimore, MD, USA., Montgomery JS; Department of Urology, University of Michigan, Ann Arbor, MI, USA., Lerner SP; Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA., Busby JE; Department of Surgery, Prisma Health, University of South Carolina School of Medicine at Greenville, Greenville, SC, USA., Poch M; Department of Genitourinary Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Crispen PL; Department of Urology, University of Florida, Gainesville, FL, USA., Steinberg GD; Department of Urology, New York University Langone Health, New York, NY, USA., Schuckman AK; Institute of Urology, University of Southern California, Los Angeles, CA, USA., Downs TM; Department of Urology, University of Wisconsin, Madison, WI, USA., Svatek RS; Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA., Mashni J; Department of Surgical Oncology, Banner MD Anderson Cancer Center, Gilbert, AZ, USA., Lane BR; Division of Urology, Spectrum Health, Michigan State University College of Human Medicine, Grand Rapids, MI, USA., Guzzo TJ; Division of Urology, University of Pennsylvania, Philadelphia, PA, USA., Bratslavsky G; Department of Urology, SUNY Upstate Medical University, Syracuse, NY, USA., Karsh LI; The Urology Center of Colorado, Denver, CO, USA., Woods ME; Department of Urology, Loyola University, Maywood, IL, USA., Brown GA; New Jersey Urology, Bloomfield, NJ, USA., Canter D; Georgia Urology, Atlanta, GA, USA., Luchey A; Department of Urology, West Virginia University Cancer Institute, Morgantown, WV, USA., Lotan Y; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA., Krupski T; Department of Urology, University of Virginia, Charlottesville, VA, USA., Inman BA; Division of Urology, Department of Surgery, Duke University, Durham, NC, USA., Williams MB; Urology of Virginia, Virginia Beach, VA, USA., Cookson MS; Department of Urology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA., Keegan KA; Department of Urology, Vanderbilt University Medical Center, Nashville, TN, USA., Andriole GL; Division of Urologic Surgery, Department of Surgery, Washington University School of Medicine in St Louis, St Louis, MO, USA., Sankin AI; Department of Urology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY, USA., Boyd A; Boyd Consultants Ltd, Crewe, UK., O'Donnell MA; Department of Urology, University of Iowa, Iowa City, IA, USA., Philipson R; Trizell Ltd, Chinnor, UK., Ylä-Herttuala S; AI Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland., Sawutz D; FKD Therapies Oy, Kuopio, Finland., Parker NR; AI Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland., McConkey DJ; Department of Urology, Greenberg Bladder Cancer Institute, Johns Hopkins University, Baltimore, MD, USA., Dinney CPN; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: cdinney@mdanderson.org.

Publikováno v: European urology [Eur Urol] 2022 Mar; Vol. 81 (3), pp. 223-228. Date of Electronic Publication: 2021 Dec 18.